Osteoboost Health Inc. just announced its sixth U.S. patent for its wearable device that uses vibration therapy to strengthen bones and help women live stronger, longer lives.
The company is tackling acritical health challenge: osteopenia, a condition affecting millions of women worldwide.
Osteoboost is the first and only FDA-cleared, non-drug prescription treatment for low bone density. Powered by NASA-inspired technology, the wearable belt targets high-risk areas like the lumbar spine and hips, using a proprietary vibration frequency to stimulate bone growth effectively.
Osteoboost’s clinical trials show up to 85% reduction in spine bone density loss and 55% reduction in hip bone density loss.
We have a conversation with CEO Laura Yecies, who has more than 30 years of experience scaling businesses. As a grandmother living with osteopenia, her journey from a successful exit to Apple to founding Osteoboost reflects her commitment to providing women with a non-invasive, science-backed alternative to medication for improving bone health.
Pheast Therapeutics
Pheast Therapeutics is a preclinical stage immuno-oncology company focused on targeting immune evasion pathways to activate the innate immune system to defy cancer.
Founded and led by scientific experts in innate immunity and cancer immunotherapy, Pheast is developing novel immunotherapies for some of the most difficult-to-treat and aggressive cancers, including ovarian cancer and triple negative breast cancer.
In late 2024, the company presented new preclinical data for PHST001, an anti-CD24 antibody drug candidate that is designed to block a key macrophage “don’t eat me” signal on cancer cells.
We spoke with CEO Roy Maute about the company and its push to beat aggressive cancers.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
